Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 249

2.

Differential inhibitory effects of cyanovirin-N, griffithsin, and scytovirin on entry mediated by envelopes of gammaretroviruses and deltaretroviruses.

Jensen SM, Ruscetti FW, Rein A, Bertolette DC, Saucedo CJ, O'Keefe BR, Jones KS.

J Virol. 2014 Feb;88(4):2327-32. doi: 10.1128/JVI.02553-13. Epub 2013 Nov 27.

3.

A multicenter blinded analysis indicates no association between chronic fatigue syndrome/myalgic encephalomyelitis and either xenotropic murine leukemia virus-related virus or polytropic murine leukemia virus.

Alter HJ, Mikovits JA, Switzer WM, Ruscetti FW, Lo SC, Klimas N, Komaroff AL, Montoya JG, Bateman L, Levine S, Peterson D, Levin B, Hanson MR, Genfi A, Bhat M, Zheng H, Wang R, Li B, Hung GC, Lee LL, Sameroff S, Heneine W, Coffin J, Hornig M, Lipkin WI.

MBio. 2012 Sep 18;3(5). pii: e00266-12. doi: 10.1128/mBio.00266-12. Print 2012.

4.

Multiple sources of contamination in samples from patients reported to have XMRV infection.

Kearney MF, Spindler J, Wiegand A, Shao W, Anderson EM, Maldarelli F, Ruscetti FW, Mellors JW, Hughes SH, Le Grice SF, Coffin JM.

PLoS One. 2012;7(2):e30889. doi: 10.1371/journal.pone.0030889. Epub 2012 Feb 20.

5.

Partial retraction. Detection of an infectious retrovirus, XMRV, in blood cells of patients with chronic fatigue syndrome.

Silverman RH, Das Gupta J, Lombardi VC, Ruscetti FW, Pfost MA, Hagen KS, Peterson DL, Ruscetti SK, Bagni RK, Petrow-Sadowski C, Gold B, Dean M, Mikovits JA.

Science. 2011 Oct 14;334(6053):176. doi: 10.1126/science.334.6053.176-a. No abstract available.

PMID:
21998366
6.

Molecular aspects of HTLV-1 entry: functional domains of the HTLV-1 surface subunit (SU) and their relationships to the entry receptors.

Jones KS, Lambert S, Bouttier M, Bénit L, Ruscetti FW, Hermine O, Pique C.

Viruses. 2011 Jun;3(6):794-810. doi: 10.3390/v3060794. Epub 2011 Jun 15. Review.

7.

Failure to confirm XMRV/MLVs in the blood of patients with chronic fatigue syndrome: a multi-laboratory study.

Simmons G, Glynn SA, Komaroff AL, Mikovits JA, Tobler LH, Hackett J Jr, Tang N, Switzer WM, Heneine W, Hewlett IK, Zhao J, Lo SC, Alter HJ, Linnen JM, Gao K, Coffin JM, Kearney MF, Ruscetti FW, Pfost MA, Bethel J, Kleinman S, Holmberg JA, Busch MP; Blood XMRV Scientific Research Working Group (SRWG).

Science. 2011 Nov 11;334(6057):814-7. doi: 10.1126/science.1213841. Epub 2011 Sep 22.

8.

Detection of an infectious retrovirus, XMRV, in blood cells of patients with chronic fatigue syndrome.

Mikovits JA, Lombardi VC, Pfost MA, Hagen KS, Ruscetti FW.

Virulence. 2010 Sep-Oct;1(5):386-90. doi: 10.4161/viru.1.5.12486.

9.

Distribution of xenotropic murine leukemia virus-related virus (XMRV) infection in chronic fatigue syndrome and prostate cancer.

Mikovits JA, Huang Y, Pfost MA, Lombardi VC, Bertolette DC, Hagen KS, Ruscetti FW.

AIDS Rev. 2010 Jul-Sep;12(3):149-52. Review.

PMID:
20842203
10.

Transient inhibition of transforming growth factor-beta1 in human diabetic CD34+ cells enhances vascular reparative functions.

Bhatwadekar AD, Guerin EP, Jarajapu YP, Caballero S, Sheridan C, Kent D, Kennedy L, Lansang MC, Ruscetti FW, Pepine CJ, Higgins PJ, Bartelmez SH, Grant MB.

Diabetes. 2010 Aug;59(8):2010-9. doi: 10.2337/db10-0287. Epub 2010 May 11.

11.

Preexisting infection with human T-cell lymphotropic virus type 2 neither exacerbates nor attenuates simian immunodeficiency virus SIVmac251 infection in macaques.

Gordon SN, Weissman AR, Cecchinato V, Fenizia C, Ma ZM, Lee TH, Zaffiri L, Andresen V, Parks RW, Jones KS, Heraud JM, Ferrari MG, Chung HK, Venzon D, Mahieux R, Murphy EL, Jacobson S, Miller CJ, Ruscetti FW, Franchini G.

J Virol. 2010 Mar;84(6):3043-58. doi: 10.1128/JVI.01655-09. Epub 2010 Jan 13.

12.

Detection of an infectious retrovirus, XMRV, in blood cells of patients with chronic fatigue syndrome.

Lombardi VC, Ruscetti FW, Das Gupta J, Pfost MA, Hagen KS, Peterson DL, Ruscetti SK, Bagni RK, Petrow-Sadowski C, Gold B, Dean M, Silverman RH, Mikovits JA.

Science. 2009 Oct 23;326(5952):585-9. doi: 10.1126/science.1179052. Epub 2009 Oct 8. Erratum in: Science. 2011 Oct 14;334(6053):176. Retraction in: Alberts B. Science. 2011 Dec 23;334(6063):1636.

13.

The receptor complex associated with human T-cell lymphotropic virus type 3 (HTLV-3) Env-mediated binding and entry is distinct from, but overlaps with, the receptor complexes of HTLV-1 and HTLV-2.

Jones KS, Huang YK, Chevalier SA, Afonso PV, Petrow-Sadowski C, Bertolette DC, Gessain A, Ruscetti FW, Mahieux R.

J Virol. 2009 May;83(10):5244-55. doi: 10.1128/JVI.02285-08. Epub 2009 Mar 11.

14.

HTLV-1 uses HSPG and neuropilin-1 for entry by molecular mimicry of VEGF165.

Lambert S, Bouttier M, Vassy R, Seigneuret M, Petrow-Sadowski C, Janvier S, Heveker N, Ruscetti FW, Perret G, Jones KS, Pique C.

Blood. 2009 May 21;113(21):5176-85. doi: 10.1182/blood-2008-04-150342. Epub 2009 Mar 6.

15.

Cell-free HTLV-1 infects dendritic cells leading to transmission and transformation of CD4(+) T cells.

Jones KS, Petrow-Sadowski C, Huang YK, Bertolette DC, Ruscetti FW.

Nat Med. 2008 Apr;14(4):429-36. doi: 10.1038/nm1745. Epub 2008 Mar 23.

PMID:
18376405
16.
17.

Modulation of lymphocyte function with inhibitory CD2: loss of NK and NKT cells.

Ortaldo JR, Mason A, Willette-Brown J, Ruscetti FW, Wine J, Back T, Stull T, Bere EW, Feigenbaum L, Winkler-Pickett R, Young HA.

Cell Immunol. 2007 Sep;249(1):8-19. Epub 2007 Nov 26.

PMID:
18039542
18.

Functional and morphologic characterization of human T cells continuously grown in vitro. J. Immunol. 1977. 119: 131-138.

Ruscetti FW, Morgan DA, Gallo RC.

J Immunol. 2007 Aug 1;179(3):1415-22. No abstract available.

19.

GLUT1 is not the primary binding receptor but is associated with cell-to-cell transmission of human T-cell leukemia virus type 1.

Takenouchi N, Jones KS, Lisinski I, Fugo K, Yao K, Cushman SW, Ruscetti FW, Jacobson S.

J Virol. 2007 Feb;81(3):1506-10. Epub 2006 Nov 15.

20.

Human T-cell leukemia virus type 1 (HTLV-1) and HTLV-2 use different receptor complexes to enter T cells.

Jones KS, Fugo K, Petrow-Sadowski C, Huang Y, Bertolette DC, Lisinski I, Cushman SW, Jacobson S, Ruscetti FW.

J Virol. 2006 Sep;80(17):8291-302.

21.

K-Ras4B proteins are expressed in the nucleolus: Interaction with nucleolin.

Birchenall-Roberts MC, Fu T, Kim SG, Huang YK, Dambach M, Resau JH, Ruscetti FW.

Biochem Biophys Res Commun. 2006 Sep 22;348(2):540-9. Epub 2006 Jul 28.

PMID:
16889753
22.

Heparan sulfate proteoglycans mediate attachment and entry of human T-cell leukemia virus type 1 virions into CD4+ T cells.

Jones KS, Petrow-Sadowski C, Bertolette DC, Huang Y, Ruscetti FW.

J Virol. 2005 Oct;79(20):12692-702.

23.

Autocrine transforming growth factor-beta regulation of hematopoiesis: many outcomes that depend on the context.

Ruscetti FW, Akel S, Bartelmez SH.

Oncogene. 2005 Aug 29;24(37):5751-63. Review.

PMID:
16123808
24.

Chemokine receptor-5 (CCR5) is a receptor for the HIV entry inhibitor peptide T (DAPTA).

Polianova MT, Ruscetti FW, Pert CB, Ruff MR.

Antiviral Res. 2005 Aug;67(2):83-92.

PMID:
16002156
25.

Induction of human T cell leukemia virus type I receptors on quiescent naive T lymphocytes by TGF-beta.

Jones KS, Akel S, Petrow-Sadowski C, Huang Y, Bertolette DC, Ruscetti FW.

J Immunol. 2005 Apr 1;174(7):4262-70.

26.

Cholesterol dependence of HTLV-I infection.

Wielgosz MM, Rauch DA, Jones KS, Ruscetti FW, Ratner L.

AIDS Res Hum Retroviruses. 2005 Jan;21(1):43-50.

27.

Alterations in mast cell function and survival following in vitro infection with human immunodeficiency viruses-1 through CXCR4.

Taub DD, Mikovits JA, Nilsson G, Schaffer EM, Key ML, Petrow-Sadowski C, Ruscetti FW.

Cell Immunol. 2004 Aug;230(2):65-80.

PMID:
15598422
28.

Ceramide, a target for antiretroviral therapy.

Finnegan CM, Rawat SS, Puri A, Wang JM, Ruscetti FW, Blumenthal R.

Proc Natl Acad Sci U S A. 2004 Oct 26;101(43):15452-7. Epub 2004 Oct 15.

29.

Tuberous sclerosis complex 2 gene product interacts with human SMAD proteins. A molecular link of two tumor suppressor pathways.

Birchenall-Roberts MC, Fu T, Bang OS, Dambach M, Resau JH, Sadowski CL, Bertolette DC, Lee HJ, Kim SJ, Ruscetti FW.

J Biol Chem. 2004 Jun 11;279(24):25605-13. Epub 2004 Apr 2.

30.

An inhibitor of glycosphingolipid metabolism blocks HIV-1 infection of primary T-cells.

Puri A, Rawat SS, Lin HM, Finnegan CM, Mikovits J, Ruscetti FW, Blumenthal R.

AIDS. 2004 Apr 9;18(6):849-58.

PMID:
15060432
31.

Update on D-ala-peptide T-amide (DAPTA): a viral entry inhibitor that blocks CCR5 chemokine receptors.

Ruff MR, Polianova M, Yang QE, Leoung GS, Ruscetti FW, Pert CB.

Curr HIV Res. 2003 Jan;1(1):51-67. Review.

PMID:
15043212
32.

Antiviral and immunological benefits in HIV patients receiving intranasal peptide T (DAPTA).

Polianova MT, Ruscetti FW, Pert CB, Tractenberg RE, Leoung G, Strang S, Ruff MR.

Peptides. 2003 Jul;24(7):1093-8.

PMID:
14499289
34.

Regulation of the cell-surface expression of an HTLV-I binding protein in human T cells during immune activation.

Nath MD, Ruscetti FW, Petrow-Sadowski C, Jones KS.

Blood. 2003 Apr 15;101(8):3085-92. Epub 2002 Dec 27.

35.
36.

Levels of phospho-Smad2/3 are sensors of the interplay between effects of TGF-beta and retinoic acid on monocytic and granulocytic differentiation of HL-60 cells.

Cao Z, Flanders KC, Bertolette D, Lyakh LA, Wurthner JU, Parks WT, Letterio JJ, Ruscetti FW, Roberts AB.

Blood. 2003 Jan 15;101(2):498-507. Epub 2002 Sep 12.

37.

Role of cholesterol in human immunodeficiency virus type 1 envelope protein-mediated fusion with host cells.

Viard M, Parolini I, Sargiacomo M, Fecchi K, Ramoni C, Ablan S, Ruscetti FW, Wang JM, Blumenthal R.

J Virol. 2002 Nov;76(22):11584-95.

38.

Hematopoietic switch from lymphoid to granulocytic development in 3LL tumor-bearing mice.

Lee JK, Back TC, Komschlies KL, Ruscetti FW, Young HA, Wiltrout RH.

In Vivo. 2001 Jul-Aug;15(4):255-63.

PMID:
11695215
39.

Infection of lymphoid cells by integration-defective human immunodeficiency virus type 1 increases de novo methylation.

Fang JY, Mikovits JA, Bagni R, Petrow-Sadowski CL, Ruscetti FW.

J Virol. 2001 Oct;75(20):9753-61.

40.
41.

Prevalence of HTLV-I-associated T-cell lymphoma.

Poiesz BJ, Papsidero LD, Ehrlich G, Sherman M, Dube S, Poiesz M, Dillon K, Ruscetti FW, Slamon D, Fang C, Williams A, Duggan D, Glaser J, Gottlieb A, Goldberg J, Ratner L, Phillips P, Han T, Friedman-Kien A, Siegal F, Rai K, Sawitsky A, Sheremata LW, Dosik H, Cunningham C, Montagna R.

Am J Hematol. 2001 Jan;66(1):32-8.

42.

The synthetic peptide WKYMVm attenuates the function of the chemokine receptors CCR5 and CXCR4 through activation of formyl peptide receptor-like 1.

Li BQ, Wetzel MA, Mikovits JA, Henderson EE, Rogers TJ, Gong W, Le Y, Ruscetti FW, Wang JM.

Blood. 2001 May 15;97(10):2941-7.

43.

Enhancement of antitumor immunity against B16 melanoma tumor using genetically modified dendritic cells to produce cytokines.

Akiyama Y, Watanabe M, Maruyama K, Ruscetti FW, Wiltrout RH, Yamaguchi K.

Gene Ther. 2000 Dec;7(24):2113-21.

44.

BP1, a new homeobox gene, is frequently expressed in acute leukemias.

Haga SB, Fu S, Karp JE, Ross DD, Williams DM, Hankins WD, Behm F, Ruscetti FW, Chang M, Smith BD, Becton D, Raimondi SC, Berg PE.

Leukemia. 2000 Nov;14(11):1867-75.

PMID:
11069021
45.

Flavonoid baicalin inhibits HIV-1 infection at the level of viral entry.

Li BQ, Fu T, Dongyan Y, Mikovits JA, Ruscetti FW, Wang JM.

Biochem Biophys Res Commun. 2000 Sep 24;276(2):534-8.

PMID:
11027509
46.

Effects of growth hormone and prolactin on hematopoiesis.

Welniak LA, Tian ZG, Sun R, Keller JR, Richards S, Ruscetti FW, Murphy WJ.

Leuk Lymphoma. 2000 Aug;38(5-6):435-45. Review.

PMID:
10953965
47.

Inhibition of the expression and function of chemokine receptors on human CD4+ leukocytes by HIV-1 envelope protein gp120.

Su SB, Ueda H, Howard OM, Grimm MC, Gong W, Ruscetti FW, Oppenheim JJ, Wang JM.

Chem Immunol. 1999;72:141-60. Review. No abstract available.

PMID:
10550935
48.

Induction of CD4+ T cell alloantigen-specific hyporesponsiveness by IL-10 and TGF-beta.

Zeller JC, Panoskaltsis-Mortari A, Murphy WJ, Ruscetti FW, Narula S, Roncarolo MG, Blazar BR.

J Immunol. 1999 Oct 1;163(7):3684-91.

49.
50.

Macaques infected with cloned simian immunodeficiency virus show recurring nef gene alterations.

Heidecker G, Muñoz H, Lloyd P, Hodge D, Ruscetti FW, Morton WR, Hu S, Benveniste RE.

Virology. 1998 Sep 30;249(2):260-74.

Supplemental Content

Loading ...
Support Center